Literature DB >> 19487711

Predictors of extensively drug-resistant pulmonary tuberculosis.

Kai Kliiman1, Alan Altraja.   

Abstract

BACKGROUND: About 40 000 cases of extensively drug-resistant tuberculosis emerge worldwide annually, but the predictors of extensive drug resistance are unclear.
OBJECTIVE: To identify risk factors for extensively drug-resistant tuberculosis and multidrug-resistant but non-extensively drug-resistant tuberculosis in patients with culture-confirmed pulmonary tuberculosis.
DESIGN: Cross-sectional, countrywide study.
SETTING: Estonia, a country with 1 of the world's highest rates of extensively drug-resistant and multidrug-resistant tuberculosis. PATIENTS: All patients with culture-confirmed pulmonary tuberculosis with clinical or radiologic evidence of active disease detected from January 2003 to December 2005. MEASUREMENTS: Risk determinants from patients' demographic characteristics, socioeconomic variables, and tuberculosis-related data or HIV status.
RESULTS: Of 1163 patients, 60 (5.2%) had extensively drug-resistant tuberculosis and 196 (16.9%) had multidrug-resistant but non-extensively drug-resistant tuberculosis. Previous antituberculosis treatment (adjusted odds ratio [OR], 10.54 [95% CI, 5.97 to 18.62]), HIV infection (OR, 3.12 [CI, 1.31 to 7.41]), homelessness (OR, 2.73 [CI, 1.15 to 6.48]), and alcohol abuse (OR, 1.98 [CI, 1.08 to 3.64]) increased risk for extensive drug resistance. Previous treatment (OR, 4.11 [CI, 2.77 to 6.08]) and age 24 years or younger (OR, 2.57 [CI, 1.09 to 6.06]), 25 to 44 years (OR, 2.64 [CI, 1.35 to 5.16]), and 45 to 64 years (OR, 2.06 [CI, 1.06 to 3.99]) were determinants of multidrug resistance. In patients age 24 years or younger, female sex (OR, 6.23 [CI, 1.02 to 37.99]) and birth outside of Estonia (OR, 82.04 [CI, 3.46 to 1945.47]) increased risk for multidrug resistance. LIMITATION: Patients' comorbid conditions and drug abuse history were not incorporated into analyses because of inconsistent source data.
CONCLUSION: Previous treatment is a common risk factor for extensively drug-resistant and multidrug-resistant tuberculosis. Reducing relapses; screening persons younger than 65 years and immigrants; and combating against HIV infection, alcoholism, and homelessness are key issues for decreasing the spread of highly drug-resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487711     DOI: 10.7326/0003-4819-150-11-200906020-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

1.  Educational inequalities in tuberculosis mortality in sixteen European populations.

Authors:  J L Álvarez; A E Kunst; M Leinsalu; M Bopp; B H Strand; G Menvielle; O Lundberg; P Martikainen; P Deboosere; R Kalediene; B Artnik; J P Mackenbach; J H Richardus
Journal:  Int J Tuberc Lung Dis       Date:  2011-11       Impact factor: 2.373

Review 2.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 3.  Infections after lung transplantation.

Authors:  Mario Nosotti; Paolo Tarsia; Letizia Corinna Morlacchi
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

Review 5.  Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies.

Authors:  Midori Kato-Maeda; John Z Metcalfe; Laura Flores
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

6.  Pulmonary intravascular talcosis mimicking miliary tuberculosis in an intravenous drug addict.

Authors:  Alan Altraja; Katre Jürgenson; Retlav Roosipuu; Tanel Laisaar
Journal:  BMJ Case Rep       Date:  2014-04-08

7.  Probing Ligand Exchange in the P450 Enzyme CYP121 from Mycobacterium tuberculosis: Dynamic Equilibrium of the Distal Heme Ligand as a Function of pH and Temperature.

Authors:  Andrew J Fielding; Kednerlin Dornevil; Li Ma; Ian Davis; Aimin Liu
Journal:  J Am Chem Soc       Date:  2017-11-20       Impact factor: 15.419

8.  Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Authors:  J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-14       Impact factor: 2.373

9.  In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.

Authors:  Mathilde Cordillot; Vincent Dubée; Sébastien Triboulet; Lionel Dubost; Arul Marie; Jean-Emmanuel Hugonnet; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis.

Authors:  Dalila Martínez; Gustavo Heudebert; Carlos Seas; German Henostroza; Martin Rodriguez; Carlos Zamudio; Robert M Centor; Cesar Herrera; Eduardo Gotuzzo; Carlos Estrada
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.